Share-Based Compensation (Tables)

6 Months Ended

Dec. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2018 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2018		6.3		$	24.50
Options granted		—		$	—
Less:
Options exercised		(0.7	)	$	24.17
Options canceled or expired		—		$	—
Options outstanding at December 31, 2018		5.6		$	24.54
Options exercisable at December 31, 2018		5.6		$	24.54

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2018 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2018		2.2		$	31.12
RSUs granted		1.2		$	47.00
Less:
RSUs vested		(0.8	)	$	32.51
RSUs canceled		(0.1	)	$	39.59
RSUs outstanding at December 31, 2018		2.5		$	37.90

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended				Six months ended
	December 31,				December 31,
	2018		2017		2018		2017
Cost of molecular diagnostic testing	$	0.2	$	0.2	$	0.3	$	0.3
Cost of pharmaceutical and clinical services		0.0		—		0.1		0.1
Research and development expense		1.1		1.2		2.3		2.1
Selling, general, and administrative expense		6.2		5.5		12.5		10.8
Total share-based compensation expense	$	7.5	$	6.9	$	15.2	$	13.3